Klotho Neurosciences, Inc.(KLTO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KLTO Klotho Neurosciences, Inc.

Pre-Mkt 12-17 05:02:47 EST

0.3900

+0.0105

+2.77%

High0.3986	Low0.3655	Vol796.26K
Open0.3702	D1 Closing0.3795	Amplitude8.72%
Mkt Cap28.29M	Tradable Cap22.14M	Total Shares72.54M
T/O304.16K	T/O Rate1.40%	Tradable Shares56.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KLTO","market":"US","secType":"STK","nameCN":"Klotho Neurosciences, Inc.","latestPrice":0.39,"timestamp":1765918800000,"preClose":0.3795,"halted":0,"volume":796255,"delay":0,"floatShares":56781700,"shares":72536722,"eps":-0.304642,"marketStatus":"Pre-Mkt","change":0.0105,"latestTime":"12-17 05:02:47 EST","open":0.3702,"high":0.3986,"low":0.3655,"amount":304157.4980252,"amplitude":0.08722,"askPrice":0.4,"askSize":110,"bidPrice":0.3567,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.304642,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765981800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.39,"postHourTrading":{"tag":"盘后","latestPrice":0.3915,"preClose":0.39,"latestTime":"19:52 EST","volume":6167,"amount":2437.1884,"timestamp":1765932733690},"volumeRatio":1.2353247448377507},"requestUrl":"/m/hq/s/KLTO/tweets","defaultTab":"tweets","newsList":[{"id":"2590036655","title":"Klotho Neuroscience Sells $15M in Series C Preferred Stock to Sigma9 Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036655","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036655?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:32","pubTimestamp":1765229545,"startTime":"0","endTime":"0","summary":"Klotho Neuroscience Inc. has announced it has entered into a Securities Purchase Agreement with Sigma9 Capital, Ltd. for a private placement of 3,400 shares of its newly designated Series C Preferred Stock at $4,400 per share. The transaction, which is an unregistered sale conducted under Section 4 of the Securities Act of 1933, is subject to closing conditions including the filing of a Certificate of Designation and completion by December 31, 2025. Each share of Series C Preferred Stock will be convertible into 10,000 shares of common stock, subject to certain ownership and regulatory limitations. No underwriters or sales commissions were involved in the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6tljZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2589884899","title":"Klotho Neurosciences Inc -  Files Prospectus for Offer and Resale by Selling Stockholders of up to 34.9 Mln Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2589884899","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589884899?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:19","pubTimestamp":1764973170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB131:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2583481495","title":"Klotho Neurosciences Q3 EPS $(0.05) Up From $(0.18) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583481495","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583481495?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:42","pubTimestamp":1763073767,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences (NASDAQ:KLTO) reported quarterly losses of $(0.05) per share. This is a 72.22 percent increase over losses of $(0.18) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853426/klotho-neurosciences-q3-eps-0-05-up-from-0-18-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","TQQQ","TSYW.SI","BK4139","USAW.SI","QID","QLD","PSQ","NQmain","KLTO","SQQQ","NVIW.SI","MNQmain","USJW.SI"],"gpt_icon":0},{"id":"2573991727","title":"Klotho and Turn allow Letter of Intent to expire","url":"https://stock-news.laohu8.com/highlight/detail?id=2573991727","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573991727?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:25","pubTimestamp":1759875909,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences (KLTO)announced that its Letter of Intent, or LoI, with Turn Biotechnologies was allowed to expire by the parties. Following c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/klotho-and-turn-allow-letter-of-intent-to-expire-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/klotho-and-turn-allow-letter-of-intent-to-expire-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2573599193","title":"BRIEF-Klotho Neurosciences Announces Expiration Of Letter Of Intent","url":"https://stock-news.laohu8.com/highlight/detail?id=2573599193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573599193?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:22","pubTimestamp":1759875734,"startTime":"0","endTime":"0","summary":"BRIEF-Klotho Neurosciences Announces Expiration Of Letter Of IntentOct 7 (Reuters) - Klotho Neurosciences Inc KLTO.O:KLOTHO NEUROSCIENCES ANNOUNCES EXPIRATION OF LETTER OF INTENTKLOTHO NEUROSCIENCES I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2573991697","title":"Klotho Neurosciences Inc: Loi With Turn Biotechnologies Allowed to Expire by Parties","url":"https://stock-news.laohu8.com/highlight/detail?id=2573991697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573991697?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:21","pubTimestamp":1759875668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2N2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2573916909","title":"Klotho Neurosciences Announces Expiration of Letter of Intent","url":"https://stock-news.laohu8.com/highlight/detail?id=2573916909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573916909?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:21","pubTimestamp":1759875668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2571347738","title":"Klotho Neurosciences Inc - to Buy $300 Mln Signed Out-Licensing and Co-Development Partnership With South Korean Pharma Cos","url":"https://stock-news.laohu8.com/highlight/detail?id=2571347738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571347738?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:31","pubTimestamp":1759235472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUABNVGCB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2571347221","title":"Klotho Neurosciences Inc - Plans to Rebrand After Deal Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2571347221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571347221?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:31","pubTimestamp":1759235472,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUABNVGCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2571034778","title":"Klotho Neurosciences Inc - to Buy Turn's Era Platform and Eturna Rna Delivery System","url":"https://stock-news.laohu8.com/highlight/detail?id=2571034778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571034778?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:31","pubTimestamp":1759235472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUABNVGCB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2571347278","title":"Press Release: Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2571347278","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571347278?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:30","pubTimestamp":1759235400,"startTime":"0","endTime":"0","summary":"NEW YORK and PALO ALTO, Calif., Sept. 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc.  today announced it has signed a Letter of Intent  to acquire select assets from Turn Biotechnologies, Inc. , a leader in induced pluripotent stem cells  and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closing conditions. If completed, the transaction would position Klotho as a leader in the development of longevity therapeutics.Under the LOI, Klotho would acquire Turn's ERA  platform and eTurna RNA delivery system. These proprietary technologies are designed to rejuvenate somatic cells and restore tissue function, creating opportunities for a long list of regenerative therapies in dermatology, ophthalmology, immunology, osteoarthritis, muscle health and diseases like amyotrophic lateral sclerosis .The longevity medicine market is one of the fastest-growing global sectors. The world's ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLCT","BK4139","KLTO"],"gpt_icon":0},{"id":"2570904952","title":"Klotho Neuroscience Extends Private Placement Agreement, Caps Share Offering at 6.76 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2570904952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570904952?lang=en_us&edition=fundamental","pubTime":"2025-09-26 04:20","pubTimestamp":1758831601,"startTime":"0","endTime":"0","summary":"Klotho Neuroscience Inc. has announced an amendment to its existing subscription agreement with Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC. Under the updated terms, the agreement has been extended until September 19, 2025, and the maximum number of shares that may be issued has been set at 6,755,000. This move is part of the company's ongoing efforts to secure additional capital for its operations and growth initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDLvj68D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2570049357","title":"Klotho Neuroscience Inc. Receives Nasdaq Delisting Warning for Failure to Maintain $1 Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2570049357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570049357?lang=en_us&edition=fundamental","pubTime":"2025-09-26 04:17","pubTimestamp":1758831457,"startTime":"0","endTime":"0","summary":"**Klotho Neuroscience Inc. Receives Nasdaq Delisting Warning** Klotho Neuroscience Inc. announced it has received a delinquency notification from the Nasdaq Stock Market for failing to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550. The company now has 180 calendar days, until March 18, 2026, to regain compliance by ensuring its closing bid price is at least $1 for ten consecutive business days. If Klotho Neuroscience fails to meet this requirement, its common stock may be delisted from Nasdaq.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDLbm7vvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2565868983","title":"Klotho Neurosciences CEO to Attend Inaugural Klotho Conference & Scientific Seminar in Irvine, California","url":"https://stock-news.laohu8.com/highlight/detail?id=2565868983","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565868983?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:03","pubTimestamp":1757333027,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences, Inc. is set to attend the Inaugural Klotho Conference & Scientific Seminar at the UC-Irvine Beal Applied Innovation Center in Irvine, California, on September 15-16, 2025. The biotechnology company, focused on advancing Klotho-based therapeutics for neurodegenerative diseases, will have its two key scientific advisors, Dr. Miguel Chillon and Dr. Assumpcio Bosch, present their research achievements on Klotho gene therapy in the treatment of ALS, Alzheimer's, and longevity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire  on September 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL2Gmgy7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2560183411","title":"Klotho Neurosciences Q2 EPS $(0.12) Down From $(0.03) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2560183411","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560183411?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:50","pubTimestamp":1755525011,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences (NASDAQ:KLTO) reported quarterly losses of $(0.12) per share. This is a 300 percent decrease over losses of $(0.03) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47185202/klotho-neurosciences-q2-eps-0-12-down-from-0-03-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO"],"gpt_icon":0},{"id":"2560402907","title":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2560402907","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560402907?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:31","pubTimestamp":1755520268,"startTime":"0","endTime":"0","summary":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development. Klotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis . This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3LV5ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2560907451","title":"Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2560907451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560907451?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUA7TMMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLTO","BK4139"],"gpt_icon":0},{"id":"2559630319","title":"Klotho Neuroscience Inc. Delays Q2 2025 Financial Report Due to Incomplete Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2559630319","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559630319?lang=en_us&edition=fundamental","pubTime":"2025-08-14 23:48","pubTimestamp":1755186494,"startTime":"0","endTime":"0","summary":"Klotho Neuroscience Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the financial period ended June 30, 2025. The delay is due to the inability to complete the financial statements in time for the necessary review and signatures prior to the report's due date. The company has filed a Late Filing Notice  with the SEC to notify of the delay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL2G3hRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2558454596","title":"Klotho Neuroscience Unveils Breakthrough in Gene Therapy Manufacturing with AAVnerGene Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2558454596","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558454596?lang=en_us&edition=fundamental","pubTime":"2025-08-12 18:00","pubTimestamp":1754992852,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences, Inc. has announced a significant advancement in the development of its KLTO-202 gene therapy candidate. The company has initiated the manufacturing process using AAVnerGene Inc.'s innovative platform technology. This partnership leverages AAVnerGene's \"AAVone\" platform, which enhances the production of AAV vectors by introducing a one-plasmid system that increases efficiency, reduces impurities, and lowers development costs. The KLTO-202 candidate, which utilizes the transformative ATHENA platform for tissue-specific targeting, aims to mitigate the risks associated with traditional AAV-vectored therapies, such as liver inflammation. While these results are promising, they have not yet been presented at any scientific conference or published in a peer-reviewed journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLcfhgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLTO"],"gpt_icon":0},{"id":"2554901537","title":"Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2554901537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554901537?lang=en_us&edition=fundamental","pubTime":"2025-07-26 09:06","pubTimestamp":1753491966,"startTime":"0","endTime":"0","summary":"Klotho Neurosciences, Inc.  has announced plans to expand its development programs beyond neurology, with a focus on technologies that enhance brain function, muscle strength, bone health, and other indicators of longevity. The company is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity, in addition to its core programs targeting neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. This expansion aims to slow biological aging and reduce age-related diseases by exploring genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3. CEO Dr. Joseph Sinkule emphasized the company's mission to identify and develop assets to delay age-related health outcomes through targeted research and intervention.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250726:nNDL4kJN4S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLTO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.klothoneuro.com","stockEarnings":[{"period":"1week","weight":-0.1333},{"period":"1month","weight":-0.1624},{"period":"3month","weight":-0.3158},{"period":"6month","weight":-0.74},{"period":"1year","weight":-0.1203},{"period":"ytd","weight":-0.1959}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062221},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.069134},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.043975},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.218192},{"month":5,"riseRate":0.5,"avgChangeRate":-0.006199},{"month":6,"riseRate":0.75,"avgChangeRate":1.150026},{"month":7,"riseRate":0.25,"avgChangeRate":-0.147403},{"month":8,"riseRate":0.25,"avgChangeRate":-0.147672},{"month":9,"riseRate":0.5,"avgChangeRate":-0.1464},{"month":10,"riseRate":0.5,"avgChangeRate":-0.038644},{"month":11,"riseRate":0.25,"avgChangeRate":-0.077658},{"month":12,"riseRate":0.5,"avgChangeRate":0.020312}],"exchange":"NASDAQ","name":"Klotho Neurosciences, Inc.","nameEN":"Klotho Neurosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Klotho Neurosciences, Inc.(KLTO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Klotho Neurosciences, Inc.(KLTO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Klotho Neurosciences, Inc.,KLTO,Klotho Neurosciences, Inc.股票,Klotho Neurosciences, Inc.股票老虎,Klotho Neurosciences, Inc.股票老虎国际,Klotho Neurosciences, Inc.行情,Klotho Neurosciences, Inc.股票行情,Klotho Neurosciences, Inc.股价,Klotho Neurosciences, Inc.股市,Klotho Neurosciences, Inc.股票价格,Klotho Neurosciences, Inc.股票交易,Klotho Neurosciences, Inc.股票购买,Klotho Neurosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Klotho Neurosciences, Inc.(KLTO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Klotho Neurosciences, Inc.(KLTO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction